Professional Marketing briefs

Share this article:

Enzo Life Sciences, a division of Enzo Biochem Inc., has named Kara Cannon head of global marketing. She was previously at the Pall Corporation, holding executive positions in diagnostics, biotechnology and biosciences. 

Healthcare market research firm Manhattan Research has released data from its Digital MedTech Physician study, which focuses on the needs of device and medtech marketers. More than 800 practicing US physicians were surveyed on the digital channels they use to learn about medical devices and how they connect with device companies. 

Concentric Pharma Advertising has launched a campaign for Oceana Therapeutics' Solesta, a device indicated to treat adult fecal incontinence. Concentric has also created the website SolestaInfo.com, which provides more information for HCPs and consumers.

ImpactRx, a company known for measuring the impact of promotion on physician prescribing behavior, has acquired TargetRx, Inc., an insight provider into the drivers of HCP behavior on pharma companies. The new company will be known as ImpactRx and led by current ImpactRx president and CEO, Gregory Ellis.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?